I had an incredible time during my recent trip to Boston, Massachusetts. I visited MIT and had the chance to connect with renowned neuroscientist and associate member of the McGovern Institute for Brain Research, John Gabrieli. We had a wonderful and fruitful conversation about the importance of research and development (R&D) and how it is a crucial investment in our future.
R&D is a very complex environment. Many of the great discoveries that have been made in the field of pharmaceutical drugs were actually at complete random. It often happened that products garnered more attention due to side effects they were causing rather than for the initial purpose they were developed. Trial and error is a big part of our sector and we need the funding, drive, and dedication to stay committed to our analyses in order to further develop and better our world.
I hope that through our work at PQE Group we can support the development of new therapies – especially in the field of mental health. According to the World Health Organization (WHO), one in seven 10 to 19-year-olds experience a mental disorder, accounting for 13% of the global burden of disease in this age group. This is a huge number and must be taken as an emergency alert for institutions and industry partners to place more effort on new non-synthetic products.
We at PQE Group strive for innovations that are beyond what the current market can offer. We work to take our planet to advanced destinations through improved technologies and research. Just because no one has ever done it before, doesn’t mean we can’t do it.